サシツズマブ ゴビテカン
“Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer”. N. Engl. J. Med. 380 (8): 741–751. (February 2019). doi:10.1056/NEJMoa1814213. PMID 30786188.
“Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer”. Expert Rev Anticancer Ther 19 (8): 673–79. (August 2019). doi:10.1080/14737140.2019.1654378. PMID 31398063.